Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells 1,800 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $6.85, for a total value of $12,330.00. Following the transaction, the insider now owns 959,873 shares of the company’s stock, valued at $6,575,130.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Candel Therapeutics Stock Down 0.9 %

Shares of CADL opened at $6.65 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62. The stock has a market capitalization of $197.88 million, a PE ratio of -5.19 and a beta of -0.95. The company’s 50-day simple moving average is $6.25 and its 200-day simple moving average is $6.48. Candel Therapeutics, Inc. has a 1 year low of $0.66 and a 1 year high of $14.30.

Candel Therapeutics (NASDAQ:CADL) last announced its earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. Analysts forecast that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Candel Therapeutics

Several hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new stake in shares of Candel Therapeutics during the second quarter worth approximately $31,000. Rhumbline Advisers acquired a new position in Candel Therapeutics during the 2nd quarter worth approximately $143,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Candel Therapeutics in the 2nd quarter valued at approximately $162,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $338,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.